C J Yeo

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial
    C J Yeo
    Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland 21287 4606, USA
    Ann Surg 232:419-29. 2000
  2. ncbi Choledochal cyst or pancreatic (retention) cyst: a case report
    Jon D Vogel
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 4606, USA
    J Gastrointest Surg 7:754-7. 2003
  3. pmc Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality
    Charles J Yeo
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Ann Surg 236:355-66; discussion 366-8. 2002
  4. ncbi Autoimmune sclerosing pancreatitis: the surgeon's perspective
    Charles J Yeo
    Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287 4606, USA
    J Gastrointest Surg 9:11-4. 2005
  5. ncbi Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma
    P Argani
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Cancer Res 61:4320-4. 2001
  6. ncbi Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts
    P Argani
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Cancer 91:1332-41. 2001
  7. ncbi The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma
    M Tascilar
    Department of Pathology, The Johns Hopkins University School of Medicine, 632 Ross Building, Baltimore, MD 21205, USA
    Clin Cancer Res 7:4115-21. 2001
  8. pmc STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas
    N Sato
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Am J Pathol 159:2017-22. 2001
  9. pmc High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells
    T A Sohn
    Departments of Surgery, Pathology, and Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Ann Surg 233:696-703. 2001
  10. ncbi Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)
    P Argani
    Department of Pathology, The Johns Hopkins Medical Institutions, 2242 Weinberg, 410 North Broadway, Baltimore, MD 21231 2410, USA
    Clin Cancer Res 7:3862-8. 2001

Detail Information

Publications103 found, 100 shown here

  1. pmc Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial
    C J Yeo
    Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland 21287 4606, USA
    Ann Surg 232:419-29. 2000
    ..To evaluate the endpoints of complications (specifically pancreatic fistula and total complications) and death in patients undergoing pancreaticoduodenectomy...
  2. ncbi Choledochal cyst or pancreatic (retention) cyst: a case report
    Jon D Vogel
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 4606, USA
    J Gastrointest Surg 7:754-7. 2003
    ..Right upper quadrant cystic lesions can be difficult to differentiate using noninvasive imaging modalities. The following case report discusses the common cystic lesions of the hepatoduodenal ligament and right sided pancreas...
  3. pmc Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality
    Charles J Yeo
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Ann Surg 236:355-66; discussion 366-8. 2002
    ..To evaluate, in a prospective, randomized single-institution trial, the end points of operative morbidity, operative mortality, and survival in patients undergoing standard versus radical (extended) pancreaticoduodenectomy...
  4. ncbi Autoimmune sclerosing pancreatitis: the surgeon's perspective
    Charles J Yeo
    Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287 4606, USA
    J Gastrointest Surg 9:11-4. 2005
  5. ncbi Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma
    P Argani
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Cancer Res 61:4320-4. 2001
    ..PSCA is a novel tumor marker for pancreatic carcinoma that has potential diagnostic and therapeutic implications. These results establish the validity of analyses of SAGE databases to identify novel tumor markers...
  6. ncbi Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts
    P Argani
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Cancer 91:1332-41. 2001
    ..Biliary tract carcinomas are clinically heterogeneous. It is not known if molecular heterogeneity underlies the clinical differences...
  7. ncbi The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma
    M Tascilar
    Department of Pathology, The Johns Hopkins University School of Medicine, 632 Ross Building, Baltimore, MD 21205, USA
    Clin Cancer Res 7:4115-21. 2001
    ..36 (95% confidence interval, 1.01-1.83; P = 0.04). CONCLUSION: Patients undergoing Whipple resection for pancreatic adenocarcinoma survive longer if their cancers express SMAD4...
  8. pmc STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas
    N Sato
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Am J Pathol 159:2017-22. 2001
    ..None of the 22 IPMNs showed hypermethylation of the STK11/LKB1 gene. These results suggest that the STK11/LKB1 gene is involved in the pathogenesis of some IPMNs...
  9. pmc High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells
    T A Sohn
    Departments of Surgery, Pathology, and Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Ann Surg 233:696-703. 2001
    ..In addition, random drug screening provides an unbiased method for identifying drugs or lead compounds for potential therapeutic use...
  10. ncbi Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)
    P Argani
    Department of Pathology, The Johns Hopkins Medical Institutions, 2242 Weinberg, 410 North Broadway, Baltimore, MD 21231 2410, USA
    Clin Cancer Res 7:3862-8. 2001
    ..In this study, we evaluate the potential utility of mesothelin as a tumor marker for pancreatic adenocarcinoma...
  11. pmc Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity
    T A Sohn
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-4606, USA
    Ann Surg 234:313-21; discussion 321-2. 2001
    ....
  12. ncbi Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma
    Eugene P Kennedy
    Department of Surgery, Thomas Jefferson University, Jefferson Medical College, 1025 Walnut Street, Suite 605 College Building, Philadelphia, PA 19107, USA
    Surg Oncol Clin N Am 16:157-76. 2007
    ..These studies, including a large randomized trial of 280 patients from Johns Hopkins University, indicate that there is no demonstrable survival benefit to extended lymphadenectomy for periampullary cancer...
  13. ncbi Gene expression profiling identifies markers of ampullary adenocarcinoma
    N Tjarda Van Heek
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Cancer Biol Ther 3:651-6. 2004
    ..001). Measurement of markers of ampullary cancer such as osteopontin may aid in the early detection and differential diagnosis of patients with periampullary lesions...
  14. ncbi Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution
    Steven C Cunningham
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    J Gastrointest Surg 9:718-25. 2005
    ..Many of the reported differences among Western series may be due to cohort differences, such as stage of disease, extent of resection, tumor type, and tumor location...
  15. ncbi Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling
    D M McCarthy
    Departments of Pathology, Surgery, and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Hum Pathol 32:638-42. 2001
    ..Additionally, Dpc4 expression can be used to differentiate recurrent or persistent adenocarcinoma from a second primary adenocarcinoma...
  16. ncbi Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct
    M Tascilar
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Clin Pathol 116:831-7. 2001
    ..Importantly, loss of Dpc4 expression has been reported in in situ carcinomas, suggesting that loss of expression should not be equated with invasive carcinoma...
  17. ncbi Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma
    T Ueki
    Department of Pathology, Johns Hopkins School of Medicine and the Johns Hopkins School of Public Health, Baltimore, Maryland 21205, USA
    Cancer Res 61:8540-6. 2001
    ..ppENK, MICP25, and 27 were variably methylated in normal gastric, duodenal, and colonic mucosae. These data indicate that aberrant methylation of ppENK and its transcriptional repression is a common event in pancreatic carcinogenesis...
  18. pmc Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p
    S C Abraham
    Division of Gastrointestinal Liver Pathology, The Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 2196, USA
    Am J Pathol 159:1619-27. 2001
    ..In addition, pancreatoblastoma may represent an extracolonic manifestation of FAP...
  19. ncbi Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression
    Steven R Hustinx
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 3:1254-61. 2004
    ..TAGmapper should prove to be a powerful tool for the discovery of novel tumor markers through assignment of uncharacterized SAGE tags...
  20. ncbi Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection
    Chanjuan Shi
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 7:353-360. 2008
    ..LigAmp quantification of mutant KRAS2 in pancreatic juice differentiates pancreatic adenocarcinoma from chronic pancreatitis, and may be a useful early detection tool for pancreatic cancer...
  21. ncbi Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival
    Taylor S Riall
    Departments of Surgery, The Sol Goldman Pancreas Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Gastrointest Surg 9:1191-204; discussion 1204-6. 2005
    ..002)...
  22. doi Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma
    Jonathan R Brody
    Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
    Mod Pathol 22:651-9. 2009
    ..In summary, although pancreatic adenosquamous carcinoma and ductal adenocarcinoma have overlapping pathologic and molecular characteristics, there are distinct differences that may be helpful in diagnostic and therapeutic strategies...
  23. pmc Genetics of the FANCA gene in familial pancreatic cancer
    C D Rogers
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205 2196, USA
    J Med Genet 41:e126. 2004
  24. pmc Intraductal papillary mucinous neoplasms of the pancreas: an updated experience
    Taylor A Sohn
    Departments of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Ann Surg 239:788-97; discussion 797-9. 2004
    ..To update the authors' experience with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas...
  25. ncbi Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases
    Denis M McCarthy
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Mod Pathol 16:272-8. 2003
    ..Although ampullary and pancreatic adenocarcinomas share histologic and molecular features, ampullary carcinomas are less likely to show loss of Dpc4 expression or K-ras gene mutations...
  26. pmc Postoperative bile duct strictures: management and outcome in the 1990s
    K D Lillemoe
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Ann Surg 232:430-41. 2000
    ..To describe the management and outcome after surgical reconstruction of 156 patients with postoperative bile duct strictures managed in the 1990s...
  27. ncbi Hypermethylation of multiple genes in pancreatic adenocarcinoma
    T Ueki
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Res 60:1835-9. 2000
    ..Thus, we conclude that many pancreatic carcinomas hypermethylate a small percentage of genes, whereas a subset displays a CIMP+ phenotype...
  28. ncbi Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas
    M Goggins
    Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Res 58:5329-32. 1998
    ..Our results indicate that the TGF-beta type I and type II receptor genes are selective targets of genetic inactivation in pancreatic and biliary cancers...
  29. pmc Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays
    Christine A Iacobuzio-Donahue
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Am J Pathol 162:1151-62. 2003
    ..The genes and expressed sequence tags presented in this study provide clues to the pathobiology of pancreatic cancer and implicate a large number of potentially new molecular markers for the detection and treatment of pancreatic cancer...
  30. ncbi Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions
    Anil V Parwani
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland 21231 2410, USA
    Mod Pathol 16:299-308. 2003
    ..It is noteworthy that all of these alterations occur at the level of carcinoma in situ...
  31. pmc Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis
    Jeffrey M Hardacre
    Department of Surgery, The Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287 4688, USA
    Ann Surg 237:853-8; discussion 858-9. 2003
    ....
  32. ncbi Cholecystectomy, liver resection, and pylorus-preserving pancreaticoduodenectomy for gallbladder cancer: report of five cases
    John R Doty
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Gastrointest Surg 6:776-80. 2002
    ..There is a select group of patients, however, in whom adding a pylorus-preserving pancreaticoduodenectomy can result in a potentially curative operation by removing extensive regional spread to the peripancreatic lymph nodes...
  33. ncbi Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer
    Hiroyuki Matsubayashi
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Cancer Biol Ther 2:652-5. 2003
    ..Furthermore, the N34S polymorphism is rarely found in patients with severe idiopathic chronic pancreatitis...
  34. pmc Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas
    Norihiro Sato
    Departments of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Am J Pathol 164:903-14. 2004
    ..0001). Our findings suggest that preoperative assessment of gene expression profiles may be able to differentiate invasive from noninvasive IPMNs...
  35. ncbi Predicting resectability of periampullary cancer with three-dimensional computed tomography
    Michael G House
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Gastrointest Surg 8:280-8. 2004
    ....
  36. ncbi Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers
    Jens Koopmann
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Clin Cancer Res 10:2386-92. 2004
    ..In this study, we evaluated serum macrophage inhibitory cytokine-1 (MIC-1) as a marker of pancreatic cancer...
  37. ncbi Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling
    Rathai Anandanadesan
    Department of Surgery, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA, USA
    J Gastrointest Surg 12:57-66. 2008
    ..An AT1R-mediated VEGF induction suggests the possibility of AT1R blockade as a novel therapeutic strategy to control angiogenesis in PDA...
  38. ncbi Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags
    Dengfeng Cao
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 3:1081-9; discussion 1090-1. 2004
    ....
  39. ncbi DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease
    Hiroyuki Matsubayashi
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Cancer Res 66:1208-17. 2006
    ..The detection and quantification of aberrantly methylated DNA in pancreatic juice is a promising approach to the diagnosis of pancreatic cancer...
  40. ncbi Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer
    Michael G House
    Department of Surgery, the Indiana University School of Medicine, Indianapolis, USA
    J Gastrointest Surg 10:138-45. 2006
    ..Patterns of liver metastases from islet cell tumors, specifically multiple bilobar metastases that are not amenable to resection and/or ablation, predict a poor outcome despite resection of the primary pancreatic tumor...
  41. ncbi Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms
    Steven R Hustinx
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Cancer Biol Ther 4:596-601. 2005
    ..4; 0.9-2.2, p = 0.14). Aberrant expression of 14-3-3sigma may contribute to the outcome of patients with pancreatic ductal adenocarcinoma...
  42. ncbi Barrett's esophagus with high grade dysplasia: surgical results and long-term outcome--an update
    Elaine E Tseng
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Gastrointest Surg 7:164-70; discussion 170-1. 2003
    ..Overall prevalence of occult adenocarcinoma remains high. We have demonstrated a declining incidence of occult cancer and treatment of earlier stage adenocarcinoma when found in this population of patients treated with esophagectomy...
  43. ncbi Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors
    Tom C Nguyen
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 4606, USA
    J Gastrointest Surg 7:1-9; discussion 9-11. 2003
    ..These results imply that no negative long-term QOL measures are associated with radical pancreaticoduodenectomy (as performed in this study) for periampullary adenocarcinoma...
  44. ncbi Diagnostic laparoscopy for periampullary and pancreatic cancer: what is the true benefit?
    Christopher J Barreiro
    The Johns Hopkins Hospital, Johns Hopkins Medical Institutions, Baltimore, MD 21287 4603, USA
    J Gastrointest Surg 6:75-81. 2002
    ..Of the 107 patients categorized as likely to be resectable, 89 were actually resected (83.2%). In contrast, only 10 of the 51 patients categorized as likely to be unresectable could be resected (19.6%)...
  45. ncbi Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47
    Anirban Maitra
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Am J Clin Pathol 118:52-9. 2002
    ..Fascin and HSP47 are novel tumor markers with potential diagnostic and therapeutic implications for pancreatic carcinoma. These results establish the usefulness of global expression platforms to identify novel tumor markers...
  46. ncbi Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer
    R H Hruban
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Dig Dis 19:76-84. 2001
    ....
  47. ncbi Homozygous deletion map at 18q21.1 in pancreatic cancer
    S A Hahn
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 56:490-4. 1996
    ....
  48. ncbi Renal cell carcinoma metastatic to the pancreas: results of surgical management
    T A Sohn
    Department of Surgery, The Johns Hopkins Medical Institutions, 600 N. Wolfe Street, Baltimore, MD 21287
    J Gastrointest Surg 5:346-51. 2001
    ..The current report suggests that pancreatic metastases from renal cell carcinoma should be managed aggressively with complete resection when possible...
  49. ncbi DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
    S A Hahn
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Science 271:350-3. 1996
    ..1. These results identify DPC4 as a candidate tumor suppressor gene whose inactivation may play a role in pancreatic and possibly other human cancers...
  50. pmc Discovery of novel tumor markers of pancreatic cancer using global gene expression technology
    Christine A Iacobuzio-Donahue
    Department of Pathology, The Johns Hopkins MedicalInstitutions, Baltimore, Maryland 21231 2410, USA
    Am J Pathol 160:1239-49. 2002
    ..The remaining 69 genes have not been implicated in pancreatic cancer before, and have immediate potential as novel therapeutic targets and tumor markers of pancreatic cancer...
  51. ncbi Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy
    Steven R Hustinx
    Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Biol Ther 4:83-6. 2005
    ..Thus, pancreatic cancer is a promising cancer type in which to explore novel chemotherapeutic strategies to exploit the selective loss of MTAP function...
  52. ncbi Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice
    Hiroyuki Matsubayashi
    Department of Pathology, Division of Biostatistics, Johns Hopkins Medical Institutions, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Clin Cancer Res 11:573-83. 2005
    ....
  53. doi HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients
    Nathan G Richards
    Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Ann Surg 252:499-505; discussion 505-6. 2010
    ..Pancreatic ductal adenocarcinoma (PDA) is a devastating disease that killed nearly 38,000 people in the United States this past year...
  54. doi Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells
    Navdeep Chehl
    Department of Surgery, Jefferson Pancreatic, Biliary and Related Cancer Center, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
    J Gastrointest Surg 13:2189-200. 2009
    ..Increasing evidence indicates that inflammation facilitates PDA growth...
  55. ncbi MKK4 status predicts survival after resection of gastric adenocarcinoma
    Steven C Cunningham
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Arch Surg 141:1095-9; discussion 1100. 2006
    ..Lack of expression of the tumor-suppressor gene MKK4 is significantly correlated with poor survival after resection of gastric adenocarcinoma...
  56. pmc Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer
    Kieran Brune
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Am J Surg Pathol 30:1067-76. 2006
    ..The multifocal nature of familial pancreatic neoplasia suggests that surveillance of these patients is warranted after partial pancreatectomy...
  57. ncbi The Whipple operation: is a radical resection of benefit?
    Charles J Yeo
    Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Adv Surg 37:1-27. 2003
  58. pmc Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma
    Noriyoshi Fukushima
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Am J Pathol 160:1573-81. 2002
    ....
  59. ncbi MUC4 expression increases progressively in pancreatic intraepithelial neoplasia
    Michael J Swartz
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Clin Pathol 117:791-6. 2002
    ..Our data help establish the patterns of MUC4 expression in neoplastic precursors in the pancreas and add further support to the progression model for pancreatic adenocarcinoma...
  60. ncbi Esophagectomy for adenocarcinoma in patients 45 years of age and younger
    J Scott Bolton
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Md. 21136, USA
    J Gastrointest Surg 5:620-5. 2001
    ..Esophagectomy may be performed with low mortality, and survival is reasonable for early-stage disease. Young patients with Barrett's esophagus are not immune from the development of adenocarcinoma and need to be screened accordingly...
  61. pmc ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma
    G H Su
    Department of Oncology, Pathology, and Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 98:3254-7. 2001
    ..Here we describe the gene structure and novel somatic mutations of the activin type I receptor, ACVR1B, in pancreatic cancer. ACVR1B has not been described previously as a mutated tumor-suppressor gene...
  62. ncbi Is outpatient laparoscopic cholecystectomy safe and cost-effective? A model to study transition of care
    L A Fleisher
    Department of Anesthesiology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Anesthesiology 90:1746-55. 1999
    ..The aim of the current trial was to determine the safety and cost savings of performing laparoscopic cholecystectomy in an outpatient setting using a "mock" outpatient setting...
  63. ncbi Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Online
    C A Moskaluk
    The Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Hum Mutat 12:70. 1998
    ..This coding change is not a known polymorphism, and occurs at a codon position in which another missese/splicing change has been shown to be linked to familial melanoma/pancreas cancer...
  64. ncbi Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma
    C A Moskaluk
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 2196, USA
    Diagn Mol Pathol 6:85-90. 1997
    ..No mutations in the coding sequences of the DPC4 gene were found; hence, it appears that germline mutations in DPC4 cannot account for many of the familial aggregations of pancreatic carcinoma...
  65. ncbi Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer
    Timothy M Pawlik
    Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD 22187 6681, USA
    Surgery 141:610-8. 2007
    ....
  66. ncbi HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract
    Donna E Hansel
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Int J Gastrointest Cancer 35:15-23. 2005
    ..We propose that HLA-G expression is upregulated in a large percentage of gastrointestinal lesions and may serve to mediate immune-responsiveness in certain instances...
  67. pmc The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase
    Christina L Costantino
    Department of Surgery, Jefferson Center for Pancreatic, Biliary and Related Cancers, Departments of Pathology and Pharmacology and Experimental Therapeutics, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Cancer Res 69:4567-72. 2009
    ..We propose that HuR levels in PDA modulate the therapeutic efficacy of gemcitabine, thus serving as a marker of the clinical utility of this common chemotherapeutic agent and a potential target for intervention in pancreatic cancer...
  68. doi Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells
    Galina Chipitsyna
    Department of Surgery, Jefferson Pancreatic, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Int J Cancer 125:276-85. 2009
    ..They provide the first insight into a nicotine-initiated signal transduction pathway that regulates OPN as a possible tumorigenic mechanism in PDA...
  69. pmc Trends in long-term survival following liver resection for hepatic colorectal metastases
    Michael A Choti
    Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Ann Surg 235:759-66. 2002
    ..To examine trends in outcomes of patients undergoing resection at a single tertiary care referral center over a 16-year period...
  70. ncbi Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes
    Hiroyuki Matsubayashi
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Clin Gastroenterol Hepatol 3:752-60. 2005
    ..Methyl group deficiency might promote carcinogenesis by inducing DNA breaks and DNA hypomethylation. We hypothesized that deficient methylenetetrahydrofolate reductase (MTHFR) genotypes could promote pancreatic cancer development...
  71. pmc DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer
    Christine A Iacobuzio-Donahue
    Department of Pathology, Surgery, and Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Clin Oncol 27:1806-13. 2009
    ..A comprehensive study of pancreatic cancers from patients who have succumbed to their disease has the potential to greatly expand our understanding of the most lethal stage of this disease and identify novel areas for intervention...
  72. ncbi Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions
    Steven C Cunningham
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore Maryland 21231, USA
    Cancer Epidemiol Biomarkers Prev 15:281-7. 2006
    ..These findings may prove useful in the diagnosis and therapeutic targeting of gastric adenocarcinoma precursor lesions...
  73. doi Retroperitoneal masses with associated human chorionic gonadotropin production: Report of two cases
    Amy S Duffield
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Clin Chim Acta 395:166-9. 2008
    ..The production of human chorionic gonadotropin (hCG) can be stimulated by both pregnancy and malignancy...
  74. ncbi Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia
    Jonathan R Brody
    Department of Surgery, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
    Mod Pathol 20:1238-44. 2007
    ....
  75. ncbi Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up
    Taylor S Riall
    Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Surgery 140:764-72. 2006
    ..Many studies have reported 5-year survival data after pancreaticoduodenectomy for periampullary adenocarcinoma. This study evaluates 10-year survival in patients surviving 5 years after initial surgery...
  76. ncbi Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma
    Jens Koopmann
    Department of Pathology and Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Cancer Epidemiol Biomarkers Prev 13:487-91. 2004
    ..One candidate tumor marker recently identified by global gene expression analysis of pancreatic cancer is the secreted glycophosphoprotein osteopontin (OPN). In this study, we evaluate OPN as a serum marker of pancreatic adenocarcinoma...
  77. ncbi Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors
    Christine A Iacobuzio-Donahue
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 10:1597-604. 2004
    ..We present the MADH4 genetic status determined on a new set of pancreatic, biliary, and duodenal cancers with comparison to the mutational data reported for various tumor types...
  78. ncbi p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis
    Christophe Rosty
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Am J Surg Pathol 27:1495-501. 2003
    ..This alteration, common to pancreatic cancer-associated PanINs, may contribute to the predisposition of patients with chronic pancreatitis to develop pancreatic ductal adenocarcinoma...
  79. pmc Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations
    Susan C Abraham
    Department of Pathology, Division of Gastrointestinal Liver Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 2196, USA
    Am J Pathol 160:1361-9. 2002
    ..Overexpression of p53 was limited to only 3 of 19 (15.8%) SPTs. These results emphasize the two distinct, divergent genetic pathways of neoplastic progression in pancreatic ductal and nonductal neoplasms...
  80. ncbi Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies
    Christine A Iacobuzio-Donahue
    Departments of Pathology, Surgery, Oncology, and Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Res 63:8614-22. 2003
    ....
  81. ncbi Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract
    Donna E Hansel
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Am J Surg Pathol 28:347-56. 2004
    ..This up-regulation appears to parallel invasive behavior and may therefore be used as a potential marker for cancer aggressiveness in this system...
  82. ncbi Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation
    Donna E Hansel
    Department of Pathology, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Cancer Res 63:7032-7. 2003
    ..We propose that APP may function to promote growth in pancreatic cancer cells via signaling through sAPP and may therefore represent a novel therapeutic target in pancreatic cancer...
  83. ncbi Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology
    Christophe Rosty
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Cancer Res 62:1868-75. 2002
    ..Taken together, these data suggest that pancreatic juice measurement of HIP/PAP-I may help to identify patients with pancreatic adenocarcinoma...
  84. ncbi Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach
    Marcia Irene Canto
    Department of Medicine Gastroenterology, Johns Hopkins Medical Institution, Baltimore, MD 21205, USA
    Clin Gastroenterol Hepatol 2:606-21. 2004
    ..We prospectively evaluated the feasibility of screening for pancreatic neoplasia in high-risk individuals...
  85. ncbi Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases
    Gregory Seidel
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Am J Surg Pathol 26:56-63. 2002
    ..Instead, other factors such as tumor location, perineural invasion, vascular invasion, and margin status after resection are far more important...
  86. ncbi Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray
    Anirban Maitra
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Mod Pathol 16:902-12. 2003
    ....
  87. pmc Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway
    Susan C Abraham
    Department of Pathology, Division of GI LiverPathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 2196, USA
    Am J Pathol 160:953-62. 2002
    ..These results indicate that ACCs are genetically distinct from pancreatic ductal adenocarcinomas, but some cases contain genetic alterations common to histologically similar pancreatoblastomas...
  88. ncbi Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater
    Donna E Hansel
    MBBS, Department of Surgery, The Johns Hopkins University School of Medicine, 720 Rutland Ave, Ross 771, Baltimore, MD 21205, USA
    J Clin Oncol 23:1811-8. 2005
    ..We assessed the expression of these putative intestinal epithelial-specific transcription factors and their influence on patient outcome...
  89. ncbi An introduction to pancreatic adenocarcinoma genetics, pathology and therapy
    Scott E Kern
    Department of Oncology, Surgery, and Pathology, The Sidney Kimmel Comphrehensive Cancer Center, John s Hopkins, Baltimore, MD, USA
    Cancer Biol Ther 1:607-13. 2002
    ..The accumulating discoveries regarding the genetic basis of pancreatic cancer and developments in the clinical management of the disease provide hope for meaningful improvements in the understanding and control of this disease...
  90. ncbi MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases
    Donna E Hansel
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Int J Gastrointest Cancer 33:141-7. 2003
    ..Expression of MAGE1 has subsequently been identified in a number of neoplastic cell types, including testicular germ cell and breast cancer cells, which has led to the development of antitumor MAGE1 vaccines...
  91. ncbi Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays
    Anirban Maitra
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Clin Cancer Res 9:5988-95. 2003
    ..Global expression microarrays can document abnormal pathways that impact on tumorigenesis and disease progression...
  92. ncbi Pancreaticoduodenectomy: role of interventional radiologists in managing patients and complications
    Taylor A Sohn
    Department of Surgery, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Blalock 606, Baltimore, MD 21287 4606, USA
    J Gastrointest Surg 7:209-19. 2003
    ....
  93. ncbi Pancreaticoduodenectomy in the very elderly
    Martin A Makary
    Department of Surgery, John Hopkins University School of Medicine and Bloomberg School of Public Health, Johns Hopkins Medical Institutions, 4940 Eastern Avenue, Baltimore, MD 21224, USA
    J Gastrointest Surg 10:347-56. 2006
    ..The advent of improved surgical outcomes and an aging population will likely result in a significant increase in the number of PDs performed in the next few decades...
  94. ncbi Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation
    E M Jaffee
    Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:145-56. 2001
    ..To determine its safety and ability to induce antitumor immune responses, we conducted a phase I trial in patients with surgically resected adenocarcinoma of the pancreas...
  95. ncbi Cholangiocarcinoma
    C J Yeo
    Department of Surgery, Johns Hopkins University, Baltimore, Maryland
    Surg Clin North Am 70:1429-47. 1990
    ..However, further data from randomized studies are necessary to support or refute this impression. Further studies of adjuvant chemotherapy or hormonal therapy will also be necessary to improve patient survival...
  96. ncbi Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene
    G H Su
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Cancer Res 58:2339-42. 1998
    ..Coexistent mutations of other tumor suppressor genes in MKK4-deficient tumors suggest that MKK4 may participate in a tumor suppressive signaling pathway distinct from DPC4, p16, p53, and BRCA2...
  97. pmc Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers
    G H Su
    Departments of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Pathol 154:1835-40. 1999
    ..Our results demonstrate that germline and somatic genetic alterations of the STK11/LKB1 gene may play a causal role in carcinogenesis and that the same gene contributes to the development of both sporadic and familial forms of cancer...
  98. ncbi Hypercalcemia and pancreatic endocrine neoplasia with elevated PTH-rP: report of two new cases and subject review
    Susanna L Matsen
    Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    J Gastrointest Surg 9:270-9. 2005
    ..We then review the literature of previous cases and delve into the pathophysiology of this peptide...
  99. doi Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature
    Agnieszka K Witkiewicz
    Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Hum Pathol 39:1548-51. 2008
    ..This case highlights the importance of carefully evaluating patients with autoimmune pancreatitis to rule out an underlying neoplasm and the importance of following those who were treated nonsurgically until the disease fully resolves...
  100. ncbi Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues
    Hiroyuki Matsubayashi
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, 21205 2196, USA
    Clin Cancer Res 9:1446-52. 2003
    ..We investigated the methylation of cyclin D2 in aging and pancreatic neoplastic development, and the utility of cyclin D2 methylation as a marker of pancreatic adenocarcinoma...
  101. ncbi Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct
    Michael A Hughes
    Therapeutic Radiologists, Inc, Kansas City, MO, USA
    Int J Radiat Oncol Biol Phys 68:178-82. 2007
    ..To examine the effect of adjuvant chemoradiation for adenocarcinoma of the distal common bile duct (DCBD) after pancreaticoduodenectomy (PD) on local control and survival...